{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:43:10Z","timestamp":1794523390582,"version":"4.9.1"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-026-02395-y","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T02:05:13Z","timestamp":1779415513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacological mechanisms underlying neurovascular alterations related to resistant and refractory migraine: CGRP pathways and beyond"],"prefix":"10.1186","volume":"27","author":[{"given":"Damiana","family":"Scuteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Kodounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Bezgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bednarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas Konstantinos","family":"Alevetsovitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Wo\u0142os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Ascens\u00e3o","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the School of Advanced Studies of the European Headache Federation (EHF-SAS)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Scuteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Kodounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Katsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Bezgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bednarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savvas Konstantinos","family":"Alevetsovitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Wo\u0142os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa Ascens\u00e3o","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"1","key":"2395_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s10194-025-02079-z","volume":"26","author":"T Takizawa","year":"2025","unstructured":"Takizawa T, Danno D, Ishii R, Suzuki S, Miura M, Tanizawa Y et al (2025) The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study. J Headache Pain 26(1):140. https:\/\/doi.org\/10.1186\/s10194-025-02079-z","journal-title":"J Headache Pain"},{"issue":"11","key":"2395_CR2","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, Zagar AJ, Kim Y, Jaffe DH et al (2022) Potential Unmet Needs in Acute Treatment of Migraine in Japan: Results of the OVERCOME (Japan) Study. Adv Ther 39(11):5176\u20135190. https:\/\/doi.org\/10.1007\/s12325-022-02289-w","journal-title":"Adv Ther"},{"key":"2395_CR3","doi-asserted-by":"publisher","first-page":"e080107","DOI":"10.1136\/bmj-2024-080107","volume":"386","author":"WK Karlsson","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA, Kokoti L, Christensen RH, Al-Khazali HM et al (2024) Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ 386:e080107. https:\/\/doi.org\/10.1136\/bmj-2024-080107","journal-title":"BMJ"},{"issue":"3","key":"2395_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40801-023-00368-0","volume":"10","author":"K Hirata","year":"2023","unstructured":"Hirata K, Komori M, Ueda K, Zagar AJ, Kim Y, Jaffe DH et al (2023) Outcomes and Factors Associated with Insufficient Effectiveness of Acute Treatments of Migraine in Japan: Results of the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME [Japan]) Study. Drugs Real World Outcomes 10(3):415\u2013428. https:\/\/doi.org\/10.1007\/s40801-023-00368-0","journal-title":"Drugs Real World Outcomes"},{"issue":"7","key":"2395_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1177\/0333102411398400","volume":"31","author":"M Lant\u00e9ri-Minet","year":"2011","unstructured":"Lant\u00e9ri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31(7):837\u2013850. https:\/\/doi.org\/10.1177\/0333102411398400","journal-title":"Cephalalgia"},{"issue":"1","key":"2395_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s10194-020-01127-0","volume":"21","author":"G Lambru","year":"2020","unstructured":"Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61. https:\/\/doi.org\/10.1186\/s10194-020-01127-0","journal-title":"J Headache Pain"},{"key":"2395_CR7","doi-asserted-by":"publisher","first-page":"104943","DOI":"10.1016\/j.ebiom.2023.104943","volume":"99","author":"R Ornello","year":"2024","unstructured":"Ornello R, Andreou AP, De Matteis E, J\u00fcrgens TP, Minen MT, Sacco S (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine 99:104943. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104943","journal-title":"EBioMedicine"},{"issue":"1","key":"2395_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s10194-020-01130-5","volume":"21","author":"S Sacco","year":"2020","unstructured":"Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM et al (2020) European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21(1):76. https:\/\/doi.org\/10.1186\/s10194-020-01130-5","journal-title":"J Headache Pain"},{"issue":"7","key":"2395_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De Dhaem O, Van Kroon A, Powers S, Schwedt TJ, Lipton R et al (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87(7):741\u2013749. https:\/\/doi.org\/10.1136\/jnnp-2015-312233","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2395_CR10","doi-asserted-by":"publisher","unstructured":"Ornello R, Andreou AP, De Matteis E, J\u00fcrgens TP, Minen MT, Sacco S (2024) Resistant and refractory migraine: clinical presentation, pathophysiology, and management. EBioMedicine 99. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104943","DOI":"10.1016\/j.ebiom.2023.104943"},{"key":"2395_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed) 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ (Clinical Res ed)"},{"issue":"6","key":"2395_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10787-009-0016-x","volume":"17","author":"KD Rainsford","year":"2009","unstructured":"Rainsford KD (2009) Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 17(6):275\u2013342. https:\/\/doi.org\/10.1007\/s10787-009-0016-x","journal-title":"Inflammopharmacology"},{"issue":"5","key":"2395_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jsps.2023.03.010","volume":"31","author":"HL Wei","year":"2023","unstructured":"Wei HL, Hu TT, Wang JJ, Wang MY, Yu YS, Zhang H (2023) Potential predictors for the efficacy of non-steroidal anti-inflammatory drugs in patients with migraine. Saudi Pharm J 31(5):692\u2013697. https:\/\/doi.org\/10.1016\/j.jsps.2023.03.010","journal-title":"Saudi Pharm J"},{"issue":"1\u20132","key":"2395_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pain.2005.03.008","volume":"115","author":"AH Ahn","year":"2005","unstructured":"Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115(1\u20132):1\u20134. https:\/\/doi.org\/10.1016\/j.pain.2005.03.008","journal-title":"Pain"},{"issue":"1","key":"2395_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s10194-010-0258-4","volume":"12","author":"A Ferrari","year":"2011","unstructured":"Ferrari A, Tiraferri I, Neri L, Sternieri E (2011) Why pharmacokinetic differences among oral triptans have little clinical importance: a comment. J Headache Pain 12(1):5\u201312. https:\/\/doi.org\/10.1007\/s10194-010-0258-4","journal-title":"J Headache Pain"},{"issue":"Suppl 2","key":"2395_CR16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1468-2982.2004.00895.x","volume":"24","author":"M L\u00e1inez","year":"2004","unstructured":"L\u00e1inez M (2004) Clinical benefits of early triptan therapy for migraine. Cephalalgia 24(Suppl 2):24\u201330. https:\/\/doi.org\/10.1111\/j.1468-2982.2004.00895.x","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"2395_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.12110","volume":"53","author":"M Pierce","year":"2013","unstructured":"Pierce M (2013) Oral triptans and nausea: treatment considerations in migraine. Headache 53(Suppl 1):17\u201320. https:\/\/doi.org\/10.1111\/head.12110","journal-title":"Headache"},{"issue":"3","key":"2395_CR18","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/ana.21897","volume":"67","author":"M De Felice","year":"2010","unstructured":"De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I et al (2010) Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol 67(3):325\u2013337. https:\/\/doi.org\/10.1002\/ana.21897","journal-title":"Ann Neurol"},{"issue":"6","key":"2395_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3233\/VES-2012-0433","volume":"21","author":"R Burstein","year":"2011","unstructured":"Burstein R, Jakubowski M, Rauch SD (2011) The science of migraine. J Vestib Res 21(6):305\u2013314. https:\/\/doi.org\/10.3233\/VES-2012-0433","journal-title":"J Vestib Res"},{"issue":"1","key":"2395_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/WNR.0b013e32834e5af3","volume":"23","author":"MD Thompson","year":"2012","unstructured":"Thompson MD, Noble-Topham S, Percy ME, Andrade DM, Ebers GC (2012) Chromosome 1p36 in migraine with aura: association study of the 5HT(1D) locus. NeuroReport 23(1):45\u201348. https:\/\/doi.org\/10.1097\/WNR.0b013e32834e5af3","journal-title":"NeuroReport"},{"issue":"7","key":"2395_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1046\/j.1468-2982.2001.00208.x","volume":"21","author":"B Gomez-Mancilla","year":"2001","unstructured":"Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings EL, Klapper JA, Diamond S et al (2001) Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 21(7):727\u2013732. https:\/\/doi.org\/10.1046\/j.1468-2982.2001.00208.x","journal-title":"Cephalalgia"},{"issue":"1\u20132","key":"2395_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2011.03.016","volume":"305","author":"H Liu","year":"2011","unstructured":"Liu H, Liu M, Wang Y, Wang XM, Qiu Y, Long JF et al (2011) Association of 5-HTT gene polymorphisms with migraine: a systematic review and meta-analysis. J Neurol Sci 305(1\u20132):57\u201366. https:\/\/doi.org\/10.1016\/j.jns.2011.03.016","journal-title":"J Neurol Sci"},{"issue":"11","key":"2395_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/0333102410362929","volume":"30","author":"M Sch\u00fcrks","year":"2010","unstructured":"Sch\u00fcrks M, Rist PM, Kurth T (2010) 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia 30(11):1296\u20131305. https:\/\/doi.org\/10.1177\/0333102410362929","journal-title":"Cephalalgia"},{"issue":"4","key":"2395_CR24","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1526-4610.1998.3804288.x","volume":"38","author":"A MaassenVanDenBrink","year":"1998","unstructured":"MaassenVanDenBrink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR (1998) 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 38(4):288\u2013291. https:\/\/doi.org\/10.1046\/j.1526-4610.1998.3804288.x","journal-title":"Headache"},{"issue":"5","key":"2395_CR25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/(SICI)1096-8628(19980605)77:5<415::AID-AJMG12>3.0.CO;2-L","volume":"77","author":"A Maassen VanDenBrink","year":"1998","unstructured":"Maassen VanDenBrink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauwerse HG, Saxena PR et al (1998) Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 77(5):415\u2013420","journal-title":"Am J Med Genet"},{"issue":"Suppl 4","key":"2395_CR26","first-page":"4s75","volume":"156","author":"JM S\u00e9nard","year":"2000","unstructured":"S\u00e9nard JM (2000) [Clinical pharmacology of triptans]. Rev Neurol 156(Suppl 4):4s75\u20134s78","journal-title":"Rev Neurol"},{"issue":"5","key":"2395_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10194-010-0241-0","volume":"11","author":"G Gentile","year":"2010","unstructured":"Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 11(5):431\u2013435. https:\/\/doi.org\/10.1007\/s10194-010-0241-0","journal-title":"J Headache Pain"},{"issue":"5","key":"2395_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/14737175.2021.1912599","volume":"21","author":"D Martinelli","year":"2021","unstructured":"Martinelli D, Bitetto V, Tassorelli C (2021) Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Rev Neurother 21(5):491\u2013502. https:\/\/doi.org\/10.1080\/14737175.2021.1912599","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"2395_CR29","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev 97(2):553\u2013622. https:\/\/doi.org\/10.1152\/physrev.00034.2015","journal-title":"Physiol Rev"},{"key":"2395_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226713","author":"TMA Abdulrahim Saleh Alrasheed","year":"2024","unstructured":"Abdulrahim Saleh Alrasheed TMA, Alshamrani RA (2024) Noor Mohammad AlMohish, Majed Mohammad Alabdali Safety and Efficacy of Atogepant for the Preventive Treatment of Migraines in Adults: A Systematic Review and Meta-Analysis. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13226713","journal-title":"J Clin Med"},{"issue":"1","key":"2395_CR31","doi-asserted-by":"publisher","first-page":"e13707","DOI":"10.1111\/cts.13707","volume":"17","author":"R Boinpally","year":"2024","unstructured":"Boinpally R, Shebley M, Trugman JM, Atogepant (2024) Mechanism of action, clinical and translational science. Clin Transl Sci 17(1):e13707. https:\/\/doi.org\/10.1111\/cts.13707","journal-title":"Clin Transl Sci"},{"issue":"1","key":"2395_CR32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40120-021-00234-7","volume":"10","author":"S Hutchinson","year":"2021","unstructured":"Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H et al (2021) Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurol Ther 10(1):235\u2013249. https:\/\/doi.org\/10.1007\/s40120-021-00234-7","journal-title":"Neurol Ther"},{"issue":"1","key":"2395_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/cpdd.1337","volume":"13","author":"R Bhardwaj","year":"2024","unstructured":"Bhardwaj R, Morris B, Bertz R, Croop R, Liu J (2024) The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75\u00a0mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study. Clin Pharmacol Drug Dev 13(1):37\u201344. https:\/\/doi.org\/10.1002\/cpdd.1337","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"2395_CR34","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2217\/pmt-2022-0054","volume":"12","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT (2022) Focus on zavegepant: the first intranasal third-generation gepant. Pain Manage 12(8):879\u2013885. https:\/\/doi.org\/10.2217\/pmt-2022-0054","journal-title":"Pain Manage"},{"issue":"3","key":"2395_CR35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737175.2022.2049758","volume":"22","author":"D Scuteri","year":"2022","unstructured":"Scuteri D, Tonin P, Nicotera P, Bagetta G, Corasaniti MT (2022) Real world considerations for newly approved CGRP receptor antagonists in migraine care. Expert Rev Neurother 22(3):221\u2013230. https:\/\/doi.org\/10.1080\/14737175.2022.2049758","journal-title":"Expert Rev Neurother"},{"issue":"9","key":"2395_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S, Zavegepant (2023) First Approval Drugs 83(9):825\u2013831. https:\/\/doi.org\/10.1007\/s40265-023-01885-6","journal-title":"First Approval Drugs"},{"key":"2395_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656","author":"D Moreno-Ajona","year":"2022","unstructured":"Moreno-Ajona D, Peter MDV-M (2022) Goadsby. New Generation Gepants: Migraine Acute and Preventive Medications. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11061656","journal-title":"J Clin Med"},{"key":"2395_CR38","doi-asserted-by":"publisher","unstructured":"Joel M, Trugman DWD, Jessica Ailani K, Lu H, Lakkis M, Finnegan A, Szegedi RB (2019) Lipton. Efficacy, safety, and tolerability of ubrogepant for the acute treatment of migraine: results from a single-attack phase 3 study, ACHIEVE II (S38.008). Neurology 92. https:\/\/doi.org\/10.1212\/WNL.92.15_supplement.S38.008","DOI":"10.1212\/WNL.92.15_supplement.S38.008"},{"issue":"10","key":"2395_CR39","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/brain\/awy228","volume":"141","author":"JH Butt","year":"2018","unstructured":"Butt JH, Rostrup E, Hansen AS, Lambertsen KL, Kruuse C (2018) Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura. Brain 141(10):2943\u20132951. https:\/\/doi.org\/10.1093\/brain\/awy228","journal-title":"Brain"},{"issue":"12","key":"2395_CR40","doi-asserted-by":"publisher","first-page":"5224","DOI":"10.1093\/brain\/awad261","volume":"146","author":"TP Do","year":"2023","unstructured":"Do TP, Deligianni C, Amirguliyev S, Snellman J, Lopez CL, Al-Karagholi MA et al (2023) Second messenger signalling bypasses CGRP receptor blockade to provoke migraine attacks in humans. Brain 146(12):5224\u20135234. https:\/\/doi.org\/10.1093\/brain\/awad261","journal-title":"Brain"},{"key":"2395_CR41","doi-asserted-by":"publisher","unstructured":"Nisar A, Ahmed Z, Yuan H (2023) Novel therapeutic targets for migraine. Biomedicines 11(2). https:\/\/doi.org\/10.3390\/biomedicines11020569","DOI":"10.3390\/biomedicines11020569"},{"issue":"5","key":"2395_CR42","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1755-5949.2010.00170.x","volume":"17","author":"TA Smitherman","year":"2011","unstructured":"Smitherman TA, Walters AB, Maizels M, Penzien DB (2011) The use of antidepressants for headache prophylaxis. CNS Neurosci Ther 17(5):462\u2013469. https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00170.x","journal-title":"CNS Neurosci Ther"},{"issue":"6","key":"2395_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/2042098612455357","volume":"3","author":"M Mula","year":"2012","unstructured":"Mula M (2012) Topiramate and cognitive impairment: evidence and clinical implications. Ther Adv Drug Saf 3(6):279\u2013289. https:\/\/doi.org\/10.1177\/2042098612455357","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"2395_CR44","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1526-4610.2011.01985.x","volume":"51","author":"P Rizzoli","year":"2011","unstructured":"Rizzoli P, Loder EW (2011) Tolerance to the beneficial effects of prophylactic migraine drugs: a systematic review of causes and mechanisms. Headache 51(8):1323\u20131335. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01985.x","journal-title":"Headache"},{"key":"2395_CR45","doi-asserted-by":"publisher","first-page":"1296577","DOI":"10.3389\/fphar.2023.1296577","volume":"14","author":"MT Corasaniti","year":"2023","unstructured":"Corasaniti MT, Lawrence GW, Bagetta G, Iannacchero R, Tarsitano A, Monteleone A et al (2023) Combination of anti-CGRP\/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety. Front Pharmacol 14:1296577. https:\/\/doi.org\/10.3389\/fphar.2023.1296577","journal-title":"Front Pharmacol"},{"key":"2395_CR46","doi-asserted-by":"publisher","unstructured":"Scuteri D, Tonin P, Nicotera P, Vulnera M, Altieri GC, Tarsitano A et al (2022) Pooled analysis of real-world evidence supports anti-CGRP mAbs and OnabotulinumtoxinA combined trial in chronic migraine. Toxins 14(8). https:\/\/doi.org\/10.3390\/toxins14080529","DOI":"10.3390\/toxins14080529"},{"key":"2395_CR47","doi-asserted-by":"publisher","unstructured":"Schiano di Cola F, Caratozzolo S, Liberini P, Rao R, Padovani A (2019) Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact Onabotulinumtoxin-A treatment. Front Neurol 10\u20132019. https:\/\/doi.org\/10.3389\/fneur.2019.00678","DOI":"10.3389\/fneur.2019.00678"},{"issue":"6","key":"2395_CR48","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40122-024-00649-8","volume":"13","author":"AM Blumenfeld","year":"2024","unstructured":"Blumenfeld AM, Mechtler L, Cook L, Rhyne C, Jenkins B, Hughes O et al (2024) Real-World Evidence of the Safety and Effectiveness of Atogepant Added to OnabotulinumtoxinA for the Preventive Treatment of Chronic Migraine: A Retrospective Chart Review. Pain Therapy 13(6):1571\u20131587. https:\/\/doi.org\/10.1007\/s40122-024-00649-8","journal-title":"Pain Therapy"},{"issue":"1","key":"2395_CR49","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/head.14244","volume":"62","author":"J Ailani","year":"2022","unstructured":"Ailani J, Blumenfeld AM (2022) Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine. Headache 62(1):106\u2013108. https:\/\/doi.org\/10.1111\/head.14244","journal-title":"Headache"},{"issue":"2","key":"2395_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2217\/pgs.13.186","volume":"15","author":"R Palmirotta","year":"2014","unstructured":"Palmirotta R, Barbanti P, Ludovici G, De Marchis ML, Ialongo C, Egeo G et al (2014) Association between migraine and ACE gene (insertion\/deletion) polymorphism: the BioBIM study. Pharmacogenomics 15(2):147\u2013155. https:\/\/doi.org\/10.2217\/pgs.13.186","journal-title":"Pharmacogenomics"},{"key":"2395_CR51","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2174\/1874205X01206010065","volume":"6","author":"V Pizza","year":"2012","unstructured":"Pizza V, Agresta A, Lamaida E, Lamaida N, Infante F, Capasso A (2012) Migraine and genetic polymorphisms: an overview. Open Neurol J 6:65\u201370. https:\/\/doi.org\/10.2174\/1874205X01206010065","journal-title":"Open Neurol J"},{"key":"2395_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2377-8-4","volume":"8","author":"E Tronvik","year":"2008","unstructured":"Tronvik E, Stovner LJ, Bovim G, White LR, Gladwin AJ, Owen K et al (2008) Angiotensin-converting enzyme gene insertion\/deletion polymorphism in migraine patients. BMC Neurol 8:4. https:\/\/doi.org\/10.1186\/1471-2377-8-4","journal-title":"BMC Neurol"},{"issue":"10","key":"2395_CR53","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1080\/17425255.2020.1803279","volume":"16","author":"CD Thomas","year":"2020","unstructured":"Thomas CD, Johnson JA (2020) Pharmacogenetic factors affecting \u03b2-blocker metabolism and response. Expert Opin Drug Metab Toxicol 16(10):953\u2013964. https:\/\/doi.org\/10.1080\/17425255.2020.1803279","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"2395_CR54","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/jnnp-2021-327992","volume":"93","author":"S de Vries Lentsch","year":"2022","unstructured":"de Vries Lentsch S, Al-Hassany L, Ferrari MD, Terwindt GM, MaassenVanDenBrink A (2022) CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab. J Neurol Neurosurg Psychiatry 93(8):911\u2013912. https:\/\/doi.org\/10.1136\/jnnp-2021-327992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2395_CR55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s10194-025-02074-4","volume":"26","author":"P Anukoolwittaya","year":"2025","unstructured":"Anukoolwittaya P, Rattanawong W, Vongvaivanich K, Pongpitakmetha T, Thanprasertsuk S, Poonpedpun T et al (2025) Expert consensus on gepants for acute and preventive treatment of migraine in Thailand. J Headache Pain 26(1):131. https:\/\/doi.org\/10.1186\/s10194-025-02074-4","journal-title":"J Headache Pain"},{"issue":"6","key":"2395_CR56","doi-asserted-by":"publisher","first-page":"333102425134692","DOI":"10.1177\/03331024251346925","volume":"45","author":"A Jaimes","year":"2025","unstructured":"Jaimes A, Rodr\u00edguez-Vico J, Pajares O, Eguilior Caffarena I, Nystrom Hern\u00e1ndez AL, G\u00f3mez A et al (2025) Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study. Cephalalgia 45(6):3331024251346925. https:\/\/doi.org\/10.1177\/03331024251346925","journal-title":"Cephalalgia"},{"issue":"2","key":"2395_CR57","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/head.14903","volume":"65","author":"M Romozzi","year":"2025","unstructured":"Romozzi M, Munaf\u00f2 A, Burgalassi A, De Cesaris F, Vigani G, Altamura C et al (2025) Pharmacological differences and switching among anti-CGRP monoclonal antibodies: A narrative review. Headache 65(2):342\u2013352. https:\/\/doi.org\/10.1111\/head.14903","journal-title":"Headache"},{"issue":"5","key":"2395_CR58","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, Proietti S, D\u2019Onofrio F, Torelli P et al (2024) Ultra-late response (>\u200924 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol 271(5):2434\u20132443. https:\/\/doi.org\/10.1007\/s00415-023-12103-4","journal-title":"J Neurol"},{"issue":"1","key":"2395_CR59","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s10194-023-01602-4","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Karsan N, Lampl C, Goadsby PJ, MaassenVanDenBrink A (2023) Revisiting dose-finding of monoclonal antibodies in migraine. J Headache Pain 24(1):69. https:\/\/doi.org\/10.1186\/s10194-023-01602-4","journal-title":"J Headache Pain"},{"issue":"3","key":"2395_CR60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.12686","volume":"80","author":"AF Russo","year":"2015","unstructured":"Russo AF (2015) CGRP as a neuropeptide in migraine: lessons from mice. Br J Clin Pharmacol 80(3):403\u2013414. https:\/\/doi.org\/10.1111\/bcp.12686","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2395_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s10194-025-02043-x","volume":"26","author":"F Martami","year":"2025","unstructured":"Martami F, Holton KF (2025) Unmasking the relationship between CGRP and glutamate: from peripheral excitation to central sensitization in migraine. J Headache Pain 26(1):101. https:\/\/doi.org\/10.1186\/s10194-025-02043-x","journal-title":"J Headache Pain"},{"issue":"1","key":"2395_CR62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, Ha WS, Messina R, Ornello R et al (2024) Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain 25(1):214. https:\/\/doi.org\/10.1186\/s10194-024-01925-w","journal-title":"J Headache Pain"},{"issue":"4","key":"2395_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/17581869.2025.2487413","volume":"15","author":"D Scuteri","year":"2025","unstructured":"Scuteri D, Lawrence GW, Iannacchero R, Trimboli M, Nicotera P, Corasaniti MT et al (2025) Efficacy and safety of mAbs anti-CGRP\/CGRP R (eptinezumab and erenumab) or atogepant in combination with onabotulinumtoxinA in refractory chronic migraine: a clinical trial protocol. Pain Manage 15(4):177\u2013181. https:\/\/doi.org\/10.1080\/17581869.2025.2487413","journal-title":"Pain Manage"},{"issue":"7\u20139","key":"2395_CR64","first-page":"37","volume":"20","author":"DW Lawrence","year":"2023","unstructured":"Lawrence DW (2023) Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report. Innovations Clin Neurosci 20(7\u20139):37\u201339","journal-title":"Innovations Clin Neurosci"},{"issue":"1","key":"2395_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s10194-021-01295-7","volume":"22","author":"D Scuteri","year":"2021","unstructured":"Scuteri D, Corasaniti MT, Tonin P, Nicotera P, Bagetta G (2021) Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy. J Headache Pain 22(1):87. https:\/\/doi.org\/10.1186\/s10194-021-01295-7","journal-title":"J Headache Pain"},{"issue":"2","key":"2395_CR66","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/s1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174\u2013182. https:\/\/doi.org\/10.1016\/s1474-4422(17)30435-0","journal-title":"Lancet Neurol"},{"issue":"Suppl 1","key":"2395_CR67","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/head.13300","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW (2018) A Phase-by-Phase Review of Migraine Pathophysiology. Headache 58(Suppl 1):4\u201316. https:\/\/doi.org\/10.1111\/head.13300","journal-title":"Headache"},{"key":"2395_CR68","doi-asserted-by":"publisher","unstructured":"Edvinsson L (2015) PACAP and its receptors in migraine pathophysiology: Commentary on Walker et al., Br J Pharmacol 171: 1521\u20131533. Br J Pharmacol 172(19):4782\u20134784. https:\/\/doi.org\/10.1111\/bph.12772","DOI":"10.1111\/bph.12772"},{"key":"2395_CR69","doi-asserted-by":"publisher","unstructured":"Leda Marina Pomes MG, Enrico Bertamino,Maurizio Simmaco, Borro M, Martelletti P (2019) Optimising migraine treatment: from drug-drug interactions to personalized medicine. The Journal of Headache and Pain. https:\/\/doi.org\/10.1186\/s10194-019-1010-3","DOI":"10.1186\/s10194-019-1010-3"},{"key":"2395_CR70","doi-asserted-by":"publisher","unstructured":"1 JMP (2018) Evaluation and management of migraine in midlife women. Menopause 25. https:\/\/doi.org\/10.1097\/GME.0000000000001157","DOI":"10.1097\/GME.0000000000001157"},{"key":"2395_CR71","doi-asserted-by":"publisher","unstructured":"Sreevani N, Ramesh B, Maheshkumar K, Thanalakshmi J (2025) Comparative analysis of CGRP, VIP and PACAP-38 levels in migraine with and without aura: a case-control study. Annals Neurosciences 09727531251340156. https:\/\/doi.org\/10.1177\/09727531251340156","DOI":"10.1177\/09727531251340156"},{"issue":"1","key":"2395_CR72","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s10194-025-02022-2","volume":"26","author":"MA Al-Karagholi","year":"2025","unstructured":"Al-Karagholi MA, Zhuang ZA, Beich S, Ashina H, Ashina M (2025) PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial. J Headache Pain 26(1):79. https:\/\/doi.org\/10.1186\/s10194-025-02022-2","journal-title":"J Headache Pain"},{"issue":"4","key":"2395_CR73","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/head.13064","volume":"57","author":"DL Hay","year":"2017","unstructured":"Hay DL, Walker CS (2017) CGRP and its receptors. Headache: J Head Face Pain 57(4):625\u2013636. https:\/\/doi.org\/10.1111\/head.13064","journal-title":"Headache: J Head Face Pain"},{"issue":"2","key":"2395_CR74","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2022","unstructured":"Russo AF, Hay DL (2022) CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev 103(2):1565\u20131644. https:\/\/doi.org\/10.1152\/physrev.00059.2021","journal-title":"Physiol Rev"},{"issue":"3","key":"2395_CR75","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/s1474-4422(21)00409-9","volume":"21","author":"L Al-Hassany","year":"2022","unstructured":"Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284\u2013294. https:\/\/doi.org\/10.1016\/s1474-4422(21)00409-9","journal-title":"Lancet Neurol"},{"issue":"10","key":"2395_CR76","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.tips.2023.07.003","volume":"44","author":"TA Rees","year":"2023","unstructured":"Rees TA, Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E (2023) Calcitonin\/PAC\u2009<\u2009sub>1 receptor splice variants: a blind spot in migraine research. Trends Pharmacol Sci 44(10):651\u2013663. https:\/\/doi.org\/10.1016\/j.tips.2023.07.003","journal-title":"Trends Pharmacol Sci"},{"key":"2395_CR77","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2147\/ndt.S282562","volume":"17","author":"C Bron","year":"2021","unstructured":"Bron C, Sutherland HG, Griffiths LR (2021) Exploring the Hereditary Nature of Migraine. Neuropsychiatr Dis Treat 17:1183\u20131194. https:\/\/doi.org\/10.2147\/ndt.S282562","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"2395_CR78","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-021-01271-1","volume":"22","author":"O Kursun","year":"2021","unstructured":"Kursun O, Yemisci M, van den Maagdenberg A, Karatas H (2021) Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain 22(1):55. https:\/\/doi.org\/10.1186\/s10194-021-01271-1","journal-title":"J Headache Pain"},{"issue":"1","key":"2395_CR79","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s10194-023-01599-w","volume":"24","author":"NB Rasmussen","year":"2023","unstructured":"Rasmussen NB, Deligianni C, Christensen CE, Karlsson WK, Al-Khazali HM, Van de Casteele T et al (2023) The effect of Lu AG09222 on PACAP38- and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: an interventional, randomized, double-blind, parallel-group, placebo-controlled study. J Headache Pain 24(1):60. https:\/\/doi.org\/10.1186\/s10194-023-01599-w","journal-title":"J Headache Pain"},{"issue":"3","key":"2395_CR80","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S1474-4422(24)00003-6","volume":"23","author":"CC Chiang","year":"2024","unstructured":"Chiang CC, Porreca F, Robertson CE, Dodick DW (2024) Potential treatment targets for migraine: emerging options and future prospects. Lancet Neurol 23(3):313\u2013324. https:\/\/doi.org\/10.1016\/S1474-4422(24)00003-6","journal-title":"Lancet Neurol"},{"key":"2395_CR81","doi-asserted-by":"publisher","unstructured":"Corasaniti MT, Bagetta G, Nicotera P, Tarsitano A, Tonin P, Sandrini G et al (2023) Safety of Onabotulinumtoxin A in chronic migraine: a systematic review and meta-analysis of randomized clinical trials. Toxins 15(5). https:\/\/doi.org\/10.3390\/toxins15050332","DOI":"10.3390\/toxins15050332"},{"issue":"11","key":"2395_CR82","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1177\/0333102414527648","volume":"34","author":"R Burstein","year":"2014","unstructured":"Burstein R, Zhang X, Levy D, Aoki KR, Brin MF (2014) Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34(11):853\u2013869. https:\/\/doi.org\/10.1177\/0333102414527648","journal-title":"Cephalalgia"},{"key":"2395_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neuropharm.2017.03.026","volume":"118","author":"J Wang","year":"2017","unstructured":"Wang J, Casals-Diaz L, Zurawski T, Meng J, Moriarty O, Nealon J et al (2017) A novel therapeutic with two SNAP-25 inactivating proteases shows long-lasting anti-hyperalgesic activity in a rat model of neuropathic pain. Neuropharmacology 118:223\u2013232. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.03.026","journal-title":"Neuropharmacology"},{"key":"2395_CR84","doi-asserted-by":"publisher","unstructured":"Lanfranco Pellesi DG-A, Rubio-Beltr\u00e1n E, Ha W-S, Messina R, Raffaele O, Igor P, Bianca R, Alejandro LR, Ruth R, Claudio T, Doga V, Marta WP, Wei W, William WG (2024) Combining treatments for migraine prophylaxis: the state-of-the-art. The Journal of Headache and Pain. https:\/\/doi.org\/10.1186\/s10194-024-01925-w","DOI":"10.1186\/s10194-024-01925-w"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-026-02395-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-026-02395-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:29:00Z","timestamp":1780554540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-026-02395-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2395"],"URL":"https:\/\/doi.org\/10.1186\/s10194-026-02395-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}